Plus Therapeutics announced on March 7, 2025, the publication of results from its Phase 1 glioma clinical trial in the peer-reviewed medical journal Nature Communications. The manuscript, titled 'Treatment of Recurrent Glioma by Rhenium (186 Re) Obisbemeda (186 RNL): a Phase 1 clinical trial,' highlights promising safety and efficacy data.
The publication revealed that patients receiving greater than 100 Gy of Rhenium (186 Re) Obisbemeda achieved a median overall survival of 17 months. This survival rate is more than double the 8-month median overall survival typically observed with standard of care for glioblastoma patients.
This peer-reviewed publication provides substantial validation for the ReSPECT-GBM clinical program. The company's ReSPECT-GBM Phase 2 trial is actively enrolling patients at leading medical centers, aiming to deliver a much-needed treatment option for this devastating disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.